WHO ICTRP trial
EN-MARK
JPRN-jRCTs031240055 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCTs031240055 |
|---|---|
| Public title | EN-MARK |
| Scientific title | A clinical study investigating the efficacy of T-DXd third line therapy and exploratory analysis of biomarker changes after first line therapy in HER2-positive unresectable advanced or recurrent gastric cancer - EN-MARK |
| Primary sponsor | Yamaguchi Kensei |
| Secondary sponsors | Sato Kazuto;Daiichi Sankyo Co., Ltd. |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Conditions | gastric cancer |
| Interventions | Collection of tumor samples (before the start of treatment in Part 1 and Part 2) |
| Registration date | Apr 26, 2024 |
| Target size | 140 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: